Site-directed mutagenesis of mouse dihydrofolate reductase. Mutants with increased resistance to methotrexate and trimethoprim - PubMed (original) (raw)
. 1988 Sep 5;263(25):12500-8.
Affiliations
- PMID: 3045118
Free article
Site-directed mutagenesis of mouse dihydrofolate reductase. Mutants with increased resistance to methotrexate and trimethoprim
J Thillet et al. J Biol Chem. 1988.
Free article
Abstract
Site-directed mutagenesis was used to generate mutants of recombinant mouse dihydrofolate reductase to test the role of some amino acids in the binding of two inhibitors, methotrexate and trimethoprim. Eleven mutations changing eight amino acids at positions all involved in hydrogen bonding or hydrophobic interactions with dihydrofolate or one of the two inhibitors were tested. Nine mutants were obtained by site-directed mutagenesis and two were spontaneous mutants previously obtained by in vivo selection (Grange, T., Kunst, F., Thillet, J., Ribadeau-Dumas, B., Mousseron, S., Hung, A., Jami, J., and Pictet, R. (1984) Nucleic Acids Res. 12, 3585-3601). The choice of the mutated positions was based on the knowledge of the active site of chicken dihydrofolate reductase established by x-ray crystallographic studies since the sequences of all known eucaryotic dihydrofolate reductases are greatly conserved. Enzymes were produced in great amounts and purified using a plasmid expressing the mouse cDNA into a dihydrofolate reductase-deficient Escherichia coli strain. The functional properties of recombinant mouse dihydrofolate reductase purified from bacterial extracts were identical to those of dihydrofolate reductase isolated from eucaryotic cells. The Km(NADPH) values for all the mutants except one (Leu-22----Arg) were only slightly modified, suggesting that the mutations had only minor effects on the ternary conformation of the enzyme. In contrast, all Km(H2folate) values were increased, since the mutations were located in the dihydrofolate binding site. The catalytic activity was also modified for five mutants with, respectively, a 6-, 10-, 36-, and 60-fold decrease of Vmax for Phe-31----Arg, Ile-7----Ser, Trp 24----Arg and Leu-22----Arg mutants and a 2-fold increase for Val-115----Pro. All the mutations affected the binding of methotrexate and six, the binding of trimethoprim: Ile-7----Ser, Leu-22----Arg, Trp-24----Arg, Phe-31----Arg, Gln-35----Pro and Phe-34----Leu. The relative variation of Ki for methotrexate and trimethoprim were not comparable from one mutant to the next, reflecting the different binding modes of the two inhibitors. The mutations which yielded the greatest increases in Ki are those which involved amino acids making hydrophobic contacts with the inhibitor.
Similar articles
- Effects of conversion of phenylalanine-31 to leucine on the function of human dihydrofolate reductase.
Prendergast NJ, Appleman JR, Delcamp TJ, Blakley RL, Freisheim JH. Prendergast NJ, et al. Biochemistry. 1989 May 30;28(11):4645-50. doi: 10.1021/bi00437a020. Biochemistry. 1989. PMID: 2765506 - Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase.
Appleman JR, Prendergast N, Delcamp TJ, Freisheim JH, Blakley RL. Appleman JR, et al. J Biol Chem. 1988 Jul 25;263(21):10304-13. J Biol Chem. 1988. PMID: 3292526 - Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation.
Dicker AP, Waltham MC, Volkenandt M, Schweitzer BI, Otter GM, Schmid FA, Sirotnak FM, Bertino JR. Dicker AP, et al. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11797-801. doi: 10.1073/pnas.90.24.11797. Proc Natl Acad Sci U S A. 1993. PMID: 8265628 Free PMC article. - In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application.
Blakley RL, Sorrentino BP. Blakley RL, et al. Hum Mutat. 1998;11(4):259-63. doi: 10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.0.CO;2-W. Hum Mutat. 1998. PMID: 9554740 Review. - Insights into enzyme function from studies on mutants of dihydrofolate reductase.
Benkovic SJ, Fierke CA, Naylor AM. Benkovic SJ, et al. Science. 1988 Mar 4;239(4844):1105-10. doi: 10.1126/science.3125607. Science. 1988. PMID: 3125607 Review.
Cited by
- Deep mutational scanning of Pneumocystis jirovecii dihydrofolate reductase reveals allosteric mechanism of resistance to an antifolate.
Rouleau FD, Dubé AK, Gagnon-Arsenault I, Dibyachintan S, Pageau A, Després PC, Lagüe P, Landry CR. Rouleau FD, et al. PLoS Genet. 2024 Apr 29;20(4):e1011252. doi: 10.1371/journal.pgen.1011252. eCollection 2024 Apr. PLoS Genet. 2024. PMID: 38683847 Free PMC article. - An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity.
Brennan A, Leech JT, Kad NM, Mason JM. Brennan A, et al. JACS Au. 2022 Apr 6;2(4):996-1006. doi: 10.1021/jacsau.2c00105. eCollection 2022 Apr 25. JACS Au. 2022. PMID: 35557753 Free PMC article. - The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
Duff MR Jr, Gabel SA, Pedersen LC, DeRose EF, Krahn JM, Howell EE, London RE. Duff MR Jr, et al. J Med Chem. 2020 Aug 13;63(15):8314-8324. doi: 10.1021/acs.jmedchem.0c00546. Epub 2020 Jul 28. J Med Chem. 2020. PMID: 32658475 Free PMC article. - Effects of Non-Natural Amino Acid Incorporation into the Enzyme Core Region on Enzyme Structure and Function.
Wong HE, Kwon I. Wong HE, et al. Int J Mol Sci. 2015 Sep 21;16(9):22735-53. doi: 10.3390/ijms160922735. Int J Mol Sci. 2015. PMID: 26402667 Free PMC article. - Puromycin- and methotrexate-resistance cassettes and optimized Cre-recombinase expression plasmids for use in yeast.
MacDonald C, Piper RC. MacDonald C, et al. Yeast. 2015 May;32(5):423-38. doi: 10.1002/yea.3069. Epub 2015 Mar 19. Yeast. 2015. PMID: 25688547 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases